Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Janne Kinnunen"'
Autor:
Mika Lehto, Alex Luojus, Olli Halminen, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Janne Kinnunen, Ossi Lehtonen, Konsta Teppo, Paula Tiili, Elis Kouki, Saga Itäinen-Strömberg, Mikko Niemi, Aapo L. Aro, Juha Hartikainen, K. E. Juhani Airaksinen
Publikováno v:
Annals of Medicine, Vol 56, Iss 1 (2024)
Background Little is known how individual time-in-therapeutic-range (TTR) impacts the effectiveness and safety of warfarin therapy compared to direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF).Objective To compare the effec
Externí odkaz:
https://doaj.org/article/73fe543e868b49939f16146669005f27
Autor:
Konsta Teppo, K. E. Juhani Airaksinen, Fausto Biancari, Jussi Jaakkola, Olli Halminen, Miika Linna, Jari Haukka, Jukka Putaala, Pirjo Mustonen, Janne Kinnunen, Alex Luojus, Juha Hartikainen, Aapo L. Aro, Mika Lehto
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 9 (2023)
Background Patients with aortic stenosis (AS) have been underrepresented in the trials evaluating direct oral anticoagulants (DOACs) in atrial fibrillation (AF). We aimed to assess whether AS impacts outcomes in patients with AF and estimate the effe
Externí odkaz:
https://doaj.org/article/75c6c24d51d44e93a782a744022c9251
Autor:
Konsta Teppo, Jussi Jaakkola, Fausto Biancari, Olli Halminen, Miika Linna, Jukka Putaala, Pirjo Mustonen, Janne Kinnunen, Santeri Jolkkonen, Mikko Niemi, Juha Hartikainen, K. E. Juhani Airaksinen, Mika Lehto
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 43, Iss , Pp 101131- (2022)
Background: Low socioeconomic status has been associated with higher risk of ischemic stroke and death in patients with atrial fibrillation (AF). However, whether socioeconomic status affects risk of bleeding events is unknown. We assessed the hypoth
Externí odkaz:
https://doaj.org/article/210e29e3622649f5ba6a9597d74caae1
Autor:
Juha Hartikainen, Jukka Putaala, Jari Haukka, Juhani K E Airaksinen, Pirjo Mustonen, Miika Linna, Olli Halminen, Janne Kinnunen, Aapo Aro, Mika Lehto, Alex Luojus, Saga Itäinen-Strömberg, Elis Kouki, Jussi Niiranen, Paula Tiili
Publikováno v:
Open Heart, Vol 9, Iss 2 (2022)
Objective Atrial fibrillation (AF) is a worldwide healthcare challenge owing to population ageing. In this study, we assessed the current trends in the incidence and prevalence of AF for the first time in an unselected, nationwide population.Methods
Externí odkaz:
https://doaj.org/article/4a47d82e839d4f52a53a0a48174770eb
Autor:
Juha Hartikainen, Jukka Putaala, Jari Haukka, Fausto Biancari, Pirjo Mustonen, Miika Linna, Konsta Teppo, Jussi Jaakkola, Olli Halminen, Janne Kinnunen, Mika Lehto, Alex Luojus, Saga Itäinen-Strömberg, Tero Penttilä, Mikko Niemi, KE Juhani Airaksinen
Publikováno v:
BMJ Open, Vol 12, Iss 8 (2022)
Objectives Mental health conditions (MHCs) have been associated with undertreatment of unrelated medical conditions, but whether patients with MHCs face disparities in receiving rhythm control therapies for atrial fibrillation (AF) is currently unkno
Externí odkaz:
https://doaj.org/article/cf6f94daeffd4a9296e9bf5959d9cf25
Autor:
Konsta Teppo, Jussi Jaakkola, Fausto Biancari, Olli Halminen, Miika Linna, Jari Haukka, Jukka Putaala, Pirjo Mustonen, Janne Kinnunen, Alex Luojus, Saga Itäinen-Strömberg, Juha Hartikainen, Aapo L. Aro, K.E. Juhani Airaksinen, Mika Lehto
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 41, Iss , Pp 101070- (2022)
Background: In patients with atrial fibrillation (AF), socioeconomic disparities have been reported in the use of oral anticoagulant therapy and outcomes, but whether income also affects the utilization of antiarrhythmic therapies (AATs) for rhythm c
Externí odkaz:
https://doaj.org/article/553cc02bdda24d92886b247edcc17575
Autor:
Konsta Teppo, Jussi Jaakkola, Fausto Biancari, Olli Halminen, Miika Linna, Jari Haukka, Jukka Putaala, Paula Tiili, Ossi Lehtonen, Mikko Niemi, Pirjo Mustonen, Janne Kinnunen, Juha Hartikainen, K. E. Juhani Airaksinen, Mika Lehto
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Low socioeconomic status has been associated with poor outcomes in patients with atrial fibrillation (AF). However, little is known about socioeconomic disparities in adherence to stroke prevention with direct oral anticoagulants (DOACs). We
Externí odkaz:
https://doaj.org/article/36206cd34b25456785526f3ad97daad7
Autor:
Paula Tiili, Ioannis Leventis, Janne Kinnunen, Ida Svedjebäck, Mika Lehto, Efstathia Karagkiozi, Dimitrios Sagris, George Ntaios, Jukka Putaala
Publikováno v:
Annals of Medicine, Vol 53, Iss 1, Pp 1613-1620 (2021)
AbstractBackground Non-vitamin K antagonist oral anticoagulants (NOAC) have superior safety and comparable efficacy profile compared to vitamin-K antagonists (VKAs), with more convenient dosing schemes. However, issues with adherence to the NOACs rem
Externí odkaz:
https://doaj.org/article/37caf9a674be486f9ea4666b89c17d84
Autor:
Konsta Teppo, Jussi Jaakkola, Ville L Langén, Fausto Biancari, Olli Halminen, Miika Linna, Jari Haukka, Jukka Putaala, Pirjo Mustonen, Janne Kinnunen, Alex Luojus, Juha Hartikainen, K E Juhani Airaksinen, Mika Lehto
Publikováno v:
PLoS ONE, Vol 17, Iss 10, p e0276612 (2022)
AimsLittle is known about rural-urban differences in the treatment and outcomes in patients with atrial fibrillation (AF). We aimed to assess whether the initiation of oral anticoagulant (OAC) therapy in patients with AF differs between those with ru
Externí odkaz:
https://doaj.org/article/3351c7e576e341afbf77459016544912
Autor:
Fausto Biancari, Konsta Teppo, Jussi Jaakkola, Olli Halminen, Miika Linna, Jari Haukka, Jukka Putaala, Pirjo Mustonen, Janne Kinnunen, Juha Hartikainen, Aapo Aro, Juhani Airaksinen, Mika Lehto
Publikováno v:
Journal of Epidemiology and Community Health. 76:736-742
Funding Information: Competing interests FB: none. KT: none. JJ: none. OH: none. JP reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e4736817b5dac2c6250c74b25df97ff
https://doi.org/10.1136/jech-2022-219190
https://doi.org/10.1136/jech-2022-219190